Abstract
The innovative drug market in China is experiencing robust growth, accompanied by increasing public demand for medications and higher expectations for coverage under the national healthcare security system. However, innovative drugs often face challenges such as insufficient clinical evidence and uncertainty regarding long-term efficacy. Achieving a balance between ensuring patient access and maintaining the financial sustainability of the healthcare security fund has therefore become a pivotal issue in healthcare reform. The United Kingdom establishes the Cancer Drugs Fund and the Innovative Medicines Fund, systematically integrates real-world evidence into reimbursement decision-making, establishing a dynamic mechanism for access and exit of high-value innovative drugs. This paper provides an in-depth analysis of the evolution, operational framework, and key design of these UK funds. It aims to offer insights for China to explore innovative drug payment models leveraging domestic healthcare data and to promote the application of real-world studies within its healthcare security framework.
Key words
real-world evidence /
innovative payment /
UK Cancer Drugs Fund /
UK Innovative Medicines Fund
Cite this article
Download Citations
Application of Real-World Evidence in the Conditional Payment of High-Value Innovative Drugs ——A Case Study of the UK Cancer Drugs Fund and Innovative Medicines Fund[J]. China Health Insurance. 2026, 0(2): 42-46 https://doi.org/10.19546/j.issn.1674-3830.2026.2.005
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] Department of Health and Social Care.Equity and Excellence: Liberating the NHS [R/OL].(2010-07-12) [2026-01-01]. https://www.gov.uk/government/publications/liberating-the-nhs-white-paper.
[2] NHS England. Achieving world-class cancer outcomes [EB/OL]. (2016-10-25)[2026-01-01]. https://www.england.nhs.uk/publication/achieving-world-class-cancer-outcomes-a-strategy-for-england-2015-2020/.
[3] National Audit Office. Investigation into the Cancer Drugs Fund [R/OL]. (2015-09-17)[2026-01-01].https://www.nao.org.uk/reports/investigation-into-the-cancer-drugs-fund/.
[4] NHS England. National Cancer Drugs Fund List [EB/OL].(2017-04-11) [2026-01-01].https://www.england.nhs.uk/publication/national-cancer-drugs-fund-list/.
[5] NHS England. National Innovative Medicines Fund List [EB/OL].(2024-07-24)[2026-01-01].https://www.england.nhs.uk/publication/national-innovative-medicines-fund-list/.
[6] 吕兰婷,张肇龙,王知,等.英国高值创新药支付保障机制研究与启示[J].中国医疗保险,2023(10): 122-128.
[7] ]NHS England. Cancer Drugs Fund[EB/OL].[2026-01-01].https://www.england.nhs.uk/cancer/cdf/.
[8] NHS England.Innovative Medicines Fund [EB/OL]. [2026-01-01].https://www.england.nhs.uk/medicines-2/innovative-medicines-fund/.
[9] NHS England. 100,000 patients receive early access to latest cancer therapies on NHS[EB/OL]. (2024-03-30) [2026-01-01]. https://www.england.nhs.uk/2024/03/100000-patients-receive-early-access-to-latest-cancer-therapies-on-nhs/.
[10] UK Parliament. Innovative Medicines Fund-Question for Department of Health and Social Care[EB/OL]. (2025-03-26) [2026-01-01]. https://questions-statements.parliament.uk/written-questions/detail/2025-03-26/41684/?utm_source=chatgpt.com.
[11] BRINKHUIS F.The Cancer Drugs Fund of England: improving access to innovative drugs or bypassing HTA informed decision-making?[D].The Netherlands: Utrecht University, 2022.
